IL-25 and Its Receptor (IL-25R) in Allergic Inflammation: Its Role in VEGF-mediated Angiogenesis

Meng, Qinggong; Wang, W.; Fang, Cailong; Fan, Y. Q.; An, Yongbo; Wang, Y.; Liu, Y.; Lee, T.H.; Corrigan, Chris J.; Sun, Yu

doi:10.1016/j.jaci.2008.12.190

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yoshino et al have demonstrated that the signaling pathways of VEGF secretion in malignant cells involve p38 MAPK and/or JNK [33]. In the airway, whereas some recent studies have indicated that induction of VEGF expression is not involved or weakly associated with p38 MAPK signaling [34,35], Leigh et al have shown that generation of VEGF in airway epithelial cells is dependent on activation of p38 MAPK [36]. Thus, the ramification of p38 MAPK signaling is complex and highly cell and organ specific.…”

Section: Discussionmentioning

confidence: 99%

Inhibition of p38 MAPK Reduces Expression of Vascular Endothelial Growth Factor in Allergic Airway Disease

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibition of p38 MAPK Reduces Expression of Vascular Endothelial Growth Factor in Allergic Airway Disease

et al. 2012

View full text Add to dashboard Cite

show abstract

T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma

Corrigan

Wang

Meng

et al. 2011

Proc. Natl. Acad. Sci. U.S.A.

125

152

View full text Add to dashboard Cite

IL-25 (IL-17E) is a T-helper cell type 2 (Th2) cytokine best described as a potentiator of Th2 memory responses. Reports of expression of its receptor, IL-25R, on airways structural cells suggest a wider role for IL-25 in remodeling. We hypothesized that IL-25 stimulates local angiogenesis in the asthmatic bronchial mucosa. Immunoreactive IL-25 + , IL-25R + , and CD31 + (endothelial) cells in sections of bronchial biopsies from asthmatics and controls were detected by immunohistochemistry. The effect of IL-25 on angiogenesis was examined using an in vitro assay. Real-time PCR was used to detect expression of IL-25R and VEGF mRNA in cultured human vascular endothelial cells (HUVEC), and a cell proliferation kit (WST-8) was used to measure the effect of IL-25 on HUVEC proliferation. Immunostaining showed that IL-25 + , IL-25R + , and CD31 + /IL-25R + cells were significantly elevated in the bronchial mucosa of asthmatics compared with controls (P < 0.003). In asthmatics, the numbers of IL-25 + cells correlated inversely with the forced expiratory volume in 1 s (r = −0.639; P = 0.01). In vitro, HUVEC constitutively expressed IL-25R, which was up-regulated further by TNF-α. IL-25 and TNF-α also increased expression of VEGF and VEGF receptors. IL-25 increased HUVEC proliferation and the number, length, and area of microvessel structures in a concentration-dependent manner in vitro. VEGF blockade, the PI3K-specific inhibitor LY294002, and the MAPK/ERK1/2 (MEK1/2)-specific inhibitor U0126 all markedly attenuated IL-25-induced angiogenesis, and the inhibitors also reduced IL-25-induced proliferation and VEGF expression. Our findings suggest that IL-25 is elevated in asthma and contributes to angiogenesis, at least partly by increasing endothelial cell VEGF/VEGF receptor expression through PI3K/Akt and Erk/MAPK pathways.

show abstract

Natural products targeting tumour angiogenesis

Lu,

Friedrich,

Efferth

2023

British J Pharmacology

View full text Add to dashboard Cite

Tumor angiogenesis is the formation of new blood vessels to support the growth of a tumor. This process is critical for tumor progression and metastasis, making it an attractive approach to cancer therapy. Natural products derived from plants, animals, or microorganisms exert anti‐angiogenic properties and can be used to inhibit tumor growth and progression. In this review, we comprehensively report on the current status of natural products against tumor angiogenesis from four perspectives until March 2023: 1) the role of pro‐angiogenic factors and antiangiogenic factors in tumor angiogenesis; 2) the development of anti‐tumor angiogenesis therapy (monoclonal antibodies, VEGFR‐targeted small molecules, and fusion proteins); 3) the summary of anti‐angiogenic natural agents, including polyphenols, polysaccharides, alkaloids, terpenoids, saponins and their mechanisms of action; 4) the future perspectives of anti‐angiogenic natural products (bioavailability improvement, testing of dosage and side effects, combination use, and discovery of unique natural‐based compounds). Our review aims to better understand the potential of natural products for drug development in inhibiting tumor angiogenesis and further aid the effective transition of these outcomes into clinical trials.

show abstract

IL-25 and Its Receptor (IL-25R) in Allergic Inflammation: Its Role in VEGF-mediated Angiogenesis

Cited by 4 publications

References 0 publications

Inhibition of p38 MAPK Reduces Expression of Vascular Endothelial Growth Factor in Allergic Airway Disease

Inhibition of p38 MAPK Reduces Expression of Vascular Endothelial Growth Factor in Allergic Airway Disease

T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma

Natural products targeting tumour angiogenesis

Contact Info

Product

Resources

About